BCRX vs. JAZZ
BCRX (BioCryst Pharmaceuticals, Inc.) and JAZZ (Jazz Pharmaceuticals plc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, BCRX returned 12.61%/yr vs 5.26%/yr for JAZZ. At a 0.28 correlation, their price movements are largely independent.
Performance
BCRX vs. JAZZ - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BCRX achieves a 19.36% return, which is significantly lower than JAZZ's 35.44% return. Over the past 10 years, BCRX has outperformed JAZZ with an annualized return of 12.61%, while JAZZ has yielded a comparatively lower 5.26% annualized return.
BCRX
- 1D
- 1.86%
- 1M
- 12.30%
- YTD
- 19.36%
- 6M
- 23.64%
- 1Y
- -6.05%
- 3Y*
- 9.92%
- 5Y*
- -11.35%
- 10Y*
- 12.61%
JAZZ
- 1D
- 1.92%
- 1M
- -3.99%
- YTD
- 35.44%
- 6M
- 35.86%
- 1Y
- 115.67%
- 3Y*
- 22.63%
- 5Y*
- 5.19%
- 10Y*
- 5.26%
BCRX vs. JAZZ - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BCRX BioCryst Pharmaceuticals, Inc. | 19.36% | 3.72% | 25.54% | -47.82% | -17.11% | 85.91% | 115.94% | -57.25% | 64.36% | -22.43% |
JAZZ Jazz Pharmaceuticals plc | 35.44% | 38.04% | 0.12% | -22.79% | 25.05% | -22.81% | 10.56% | 20.43% | -7.94% | 23.50% |
Correlation
The correlation between BCRX and JAZZ is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.27 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.30 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.28 |
Correlation (All Time) Calculated using the full available price history since Jun 1, 2007 | 0.28 |
Fundamentals
BCRX:
$2.26B
JAZZ:
$15.22B
BCRX:
-$2.03
JAZZ:
$0.47
BCRX:
2.37
JAZZ:
3.24
BCRX:
$885.72M
JAZZ:
$4.44B
BCRX:
$167.34M
JAZZ:
$2.97B
BCRX:
-$374.88M
JAZZ:
$336.83M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BCRX vs. JAZZ — Risk / Return Rank
BCRX
JAZZ
BCRX vs. JAZZ - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for BioCryst Pharmaceuticals, Inc. (BCRX) and Jazz Pharmaceuticals plc (JAZZ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BCRX | JAZZ | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.27 | ||
| Sortino ratioReturn per unit of downside risk | -4.56 | ||
| Omega ratioGain probability vs. loss probability | 1.01 | 1.59 | -0.58 |
| Calmar ratioReturn relative to maximum drawdown | -0.16 | 10.19 | -10.35 |
| Martin ratioReturn relative to average drawdown | -0.29 | 25.34 | -25.63 |
Loading charts...
Drawdowns
BCRX vs. JAZZ - Drawdown Comparison
The maximum BCRX drawdown since its inception was -97.74%, roughly equal to the maximum JAZZ drawdown of -96.90%. Use the drawdown chart below to compare losses from any high point for BCRX and JAZZ.
Loading charts...
Drawdown Indicators
| BCRX | JAZZ | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.74% | -96.90% | -0.84% |
Max Drawdown (1Y)Largest decline over 1 year | -37.16% | -11.42% | -25.74% |
Max Drawdown (3Y)Largest decline over 3 years | -47.85% | -32.71% | -15.14% |
Max Drawdown (5Y)Largest decline over 5 years | -79.10% | -47.09% | -32.01% |
Max Drawdown (10Y)Largest decline over 10 years | -83.69% | -52.10% | -31.59% |
Current DrawdownCurrent decline from peak | -71.90% | -4.09% | -67.81% |
Average DrawdownAverage peak-to-trough decline | -69.65% | -27.35% | -42.30% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.76% | 4.58% | +16.18% |
Volatility
BCRX vs. JAZZ - Volatility Comparison
BioCryst Pharmaceuticals, Inc. (BCRX) has a higher volatility of 12.10% compared to Jazz Pharmaceuticals plc (JAZZ) at 8.10%. This indicates that BCRX's price experiences larger fluctuations and is considered to be riskier than JAZZ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BCRX | JAZZ | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.10% | 8.10% | +4.00% |
Volatility (6M)Calculated over the trailing 6-month period | 34.51% | 23.46% | +11.05% |
Volatility (1Y)Calculated over the trailing 1-year period | 44.89% | 37.15% | +7.74% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 62.06% | 31.84% | +30.22% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 72.62% | 32.77% | +39.85% |
Dividends
BCRX vs. JAZZ - Dividend Comparison
Neither BCRX nor JAZZ has paid dividends to shareholders.
Financials
BCRX vs. JAZZ - Financials Comparison
This section allows you to compare key financial metrics between BioCryst Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
BCRX and JAZZ have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BCRX has higher volatility (12.10%) compared to JAZZ (8.10%). In terms of maximum drawdown, BCRX dropped -97.74% vs JAZZ's -96.90%.
JAZZ currently has the higher Sharpe Ratio (3.13 vs -0.14), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BCRX and JAZZ
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer